Cost minimization analysis of subcutaneous trastuzumab versus intravenous biosimilar trastuzumab: policy recommendations for breast cancer treatment in Malaysia

Quality of care in the course of subcutaneous versus intravenous trastuzumab administration in patients with breast cancer: an integrated time–motion study with mixed-methods research

(2023) Hsiang-Wen Lin et al.   BMJ Open

OUT OF POCKETS SPENDING AMONG BREAST CANCER WOMEN RECEIVING OUT-PATIENT TREATMENT IN A TERTIARY TEACHING HOSPITAL IN KUALA LUMPUR MALAYSIA

(2022) Jamilah Yusoff et al.   Malaysian Journal of Public Health Medicine

Perspectives toward biosimilars among oncologists: A Malaysian survey

(2022) Soon Cien Chong et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

Time-to-Treatment of Oral Cancer and Potentially Malignant Oral Disorders: Findings in Malaysian Public Healthcare

(2022) Sivaraj Raman et al.   Dentistry Journal

Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice

(2021) Cornelius F. Waller et al.   BRITISH JOURNAL OF CANCER

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2021) Hyuna Sung et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Cost-minimization analysis of subcutaneous versus intravenous trastuzumab administration in Chilean patients with HER2-positive early breast cancer

(2020) Luis Rojas et al.   PLoS One

The molecular landscape of Asian breast cancers reveals clinically relevant population-specific differences

(2020) Jia-Wern Pan et al.   Nature Communications

Economic benefits of subcutaneous trastuzumab administration: A single institutional study from Karolinska University Hospital in Sweden

(2019) Elham Hedayati et al.   PLoS One

A multidisciplinary perspective on the subcutaneous administration of trastuzumab in HER2-positive breast cancer

(2019) S. Dent et al.   Current Oncology

Cost Minimization Analysis of Intravenous or Subcutaneous Trastuzumab Treatment in Patients With HER2-Positive Breast Cancer in Ireland

(2019) Gary L. O'Brien et al.   Clinical Breast Cancer

Budget Impact of Switching to Biosimilar Trastuzumab (CT-P6) for the Treatment of Breast Cancer and Gastric Cancer in 28 European Countries

(2019) Seung-Mi Lee et al.   BIODRUGS

The Global Need for a Trastuzumab Biosimilar for Patients With HER2-Positive Breast Cancer

(2018) Kimberly Blackwell et al.   Clinical Breast Cancer

Subcutaneous trastuzumab (Herceptin) versus intravenous trastuzumab for the treatment of patients with HER2-positive breast cancer: A time, motion and cost assessment study in a lean operating day care oncology unit

(2018) Wiebren A.A. Tjalma et al.   European Journal of Obstetrics & Gynecology and Reproductive Biology

Societal cost of subcutaneous and intravenous trastuzumab for HER2-positive breast cancer – An observational study prospectively recording resource utilization in a Swedish healthcare setting

(2016) Sara Olofsson et al.   BREAST

A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer

(2016) Erwin De Cock et al.   Cancer Medicine

Budget Impact Analysis of Biosimilar Trastuzumab for the Treatment of Breast Cancer in Croatia

(2016) August Cesarec et al.   Applied Health Economics and Health Policy

Subcutaneous Trastuzumab for HER2-positive Breast Cancer – Evidence and Practical Experience in 7 German Centers

(2015) C. Jackisch et al.   GEBURTSHILFE UND FRAUENHEILKUNDE

Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831

(2014) Edith A. Perez et al.   JOURNAL OF CLINICAL ONCOLOGY

Costing Hospital Surgery Services: The Method Matters

(2014) Gregoire Mercier et al.   PLoS One

Cost-Minimization Analysis of Trastuzumab Intravenous Versus Trastuzumab Subcutaneous for the Treatment of Patients With HER2+ Early Breast Cancer And Metastatic Breast Cancer in Greece

(2014) C. Mylonas et al.   VALUE IN HEALTH

Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study

(2013) Xavier Pivot et al.   LANCET ONCOLOGY

Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial

(2012) Gustavo Ismael et al.   LANCET ONCOLOGY